Virginia Commonwealth University

Make it real.

Featured Researcher

Research Expertise and Focus

  • Breast cancer research, immunotherapy, T-cell biology, use of neoadjuvant therapy to increase the chance for breast conservation among women with breast cancer
  • Cranial stimulation for chemotherapy symptoms in breast cancer, 1R01CA127446-01A2. Funded 2009-2012 by NIH/NCI, $1,193,773. D. Lyon is principal investigator.
  • This biobehavioral, randomized clinical trial, will examine the effects of cranial microcurrent electrical stimulation on ameliorating psychoneurologic symptoms (depression, anxiety, fatigue, pain and sleep disturbances) in women with early stage breast cancer during the adjuvant chemotherapy treatment period.
  • In vivo imaging of adoptively transferred T lymphocytes in tumor-bearing mice. Funded 2010-2011 through Massey Cancer Center’s Pilot Project program at $30,000. Co-investigator
  • Choosing neoadjuvant chemotherapy versus hormonal therapy for breast cancer based on gene expression profile. 2011-2012, genomic health, Massey Cancer Center Protocol #: MCCHM13311
  • Sequential common gamma-chain cytokines can expand tumor antigen-reactive T-cells that are resistant to cancer-associated immune suppression and generate long-term memory responses against HER-2/neu. Funded 2011-2012 by Commonwealth Health Research Board, at $100,000 total direct costs. Co-investigator
  • Genetic profiling: New prognostic and predictive assays for breast cancer therapy. Funded 2004-2007 by AACR/V Foundation for $100,000 a year, plus matching funds from Massey Cancer Center. Co-principal investigator

Professional Highlights

Memberships and Leadership

  • Chairman, Massey Cancer Center Protocol Review and Monitoring Committee (PRMC), 2011-present
  • Interim Associate Director for Clinical Research, Massey Cancer Center, 2012-present
  • Massey Cancer Center Cancer Research Informatics and Services (CRIS) Internal Advisory Board, 2010-present
  • VCUHS Malpractice Committee (now Self-Insurance Committee), 1995-present
  • Massey Cancer Center Clinical Oncology Services Executive Committee, 1993-present
  • Massey Cancer Center Peer Review Committee and Clinical Trials Review Committee (now Protocol Review and Monitoring Committee), 1993-present
  • Board of Trustees, Richmond Academy of Medicine, 2010-2012
  • Co-leader, Developmental Therapeutics Program, Massey Cancer Center, 2010
  • President, Virginia Chapter of the American College of Surgeons, 2002-2003
  • Chairman, Society of Surgical Oncology Issues and Government Affairs Committee, 2000-2003
  • Executive committee/board of directors, National Surgical Adjuvant Breast and Bowel Project, 1991-1996
  • Executive Committee of the Faculty, Virginia Commonwealth University School of Medicine, 1993-1994


  • Distinguished Investigator Lifetime Achievement Award, NSABP (National Surgical Adjuvant Breast and Bowel Project) Foundation Inc., 2009
  • MCV Alumni Association Outstanding Alumnus Award, 2009
  • Richmond’s Best Doctors, 1998, 2000, 2001, 2004, 2006, 2008, 2010, 2011
  • America’s Top Doctors for Cancer (Castle Connolly Guides), 2008, 2009, 2010
  • Top Docs for Women in Richmond Area; Top Doc in Breast Health, for Breast Cancer Treatment, 2007, 2009
  • “Best Doctors in America, Surgical Oncology” (Best Doctors Inc.), 2006, 2008


  • Reviewer for numerous publications, including Journal of Surgical Oncology, Cancer Research and Journal of the National Cancer Institute
  • Editorial board, Journal of Clinical Oncology, 2006-2009
  • Editorial board, Annals of Surgical Oncology, 1996-2003
  • Breast Section Editor, Journal of Surgical Oncology, 2005-present

Education and Training

  • Ph.D. and M.D., Virginia Commonwealth University
  • B.A., Yale University, New Haven, Conn.
  • Fellowship in surgical oncology, VCU Medical Center
  • Residencies, Brigham and Women’s Hospital, Boston, and University of Glasgow, Scotland
  • Surgical internship, Peter Bent Brigham Hospital, Boston

Selected Publications

Payne KK, Keim RC, Graham L, Idowu MO, Wan W, Wang XY, Toor AA, Bear HD, Manjili MH. J Leukoc Biol. Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells. 2016 Feb 29. pii: jlb.5A1215-580R. [Epub ahead of print] PMID: 26928306

Tarazi WW, Bradley CJ, Harless DW, Bear HD, Sabik LM. Medicaid expansion and access to care among cancer survivors: a baseline overview. J Cancer Surviv. 2015 Dec 11. [Epub ahead of print] PubMed PMID: 26662864.

Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muzi M, Cormack J, Muzi JP, Pryma DA, Specht JM, Hovanessian-Larsen L, Miliziano J, Mallett S, Shields AF, Mankoff DA; ACRIN 668 Investigative Team. A Phase II Study of 3′-Deoxy-3′-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688. J Nucl Med. 2015 Nov;56(11):1681-9. doi: 10.2967/jnumed.115.160663. Epub 2015 Sep 10. PubMed PMID:26359256.

Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1037-48. doi: 10.1016/S1470-2045(15)00041-8. Epub 2015 Aug  10. PubMed PMID: 26272770; PubMed Central PMCID: PMC4624323.

Aboalela N, Lyon D, Elswick RK Jr, Kelly DL, Brumelle J, Bear HD, Jackson-Cook C. Perceived Stress Levels, Chemotherapy, Radiation Treatment and Tumor Characteristics Are Associated with a Persistent Increased Frequency of Somatic Chromosomal Instability in Women Diagnosed with Breast Cancer: A One Year Longitudinal Study. PLoS One. 2015 Jul 15;10(7):e0133380. doi:10.1371/journal.pone.0133380. eCollection 2015. PubMed PMID: 26177092; PubMed Central PMCID: PMC4503400.

Zoon CK, Wan W, Graham L, Bear HD. Addition of interleukin-21 for expansion of T-cells for adoptive immunotherapy of murine melanoma. Int J Mol Sci. 2015 Apr 20;16(4):8744-60. doi: 10.3390/ijms16048744. PubMed PMID: 25903148; PubMed Central PMCID: PMC4425106.

Youniss FM, Sundaresan G, Graham LJ, Wang L, Berry CR, Dewkar GK, Jose P, BearHD, Zweit J. Near-infrared imaging of adoptive immune cell therapy in breast cancer model using cell membrane labeling. PLoS One. 2014 Oct 21;9(10):e109162. doi: 10.1371/journal.pone.0109162. eCollection 2014. PubMed PMID: 25334026; PubMed Central PMCID: PMC4204826.

Payne KK, Bear HD, Manjili MH. Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy. Future Oncol. 2014 Aug;10(10):1779-94. doi: 10.2217/fon.14.97. Review. Erratum in: Future Oncol. 2014 Oct;10(13):2098. PubMed PMID: 25303057.

Martin RK, Saleem SJ, Folgosa L, Zellner HB, Damle SR, Nguyen GK, Ryan JJ, Bear HD, Irani AM, Conrad DH. Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells. J Leukoc Biol. 2014 Jul;96(1):151-9. doi: 10.1189/jlb.5A1213-644R. Epub 2014 Mar 7. PubMed PMID: 24610880; PubMed Central PMCID: PMC4056279.

Morales JK, Saleem SJ, Martin RK, Saunders BL, Barnstein BO, Faber TW, Pullen  NA, Kolawole EM, Brooks KB, Norton SK, Sturgill J, Graham L, Bear HD, Urban JF Jr, Lantz CS, Conrad DH, Ryan JJ. Myeloid-derived suppressor cells enhance IgE-mediated mast cell responses. J Leukoc Biol. 2014 Apr;95(4):643-50. doi: 10.1189/jlb.0913510. Epub 2013 Dec 12. PubMed PMID: 24338630; PubMed Central PMCID: PMC3958743

Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang XY, Dumur CI, Bedognetti D, Tomei S, Ascierto PA, Shanker A, Bear HD, Wang E, Marincola FM, De Maria A, Manjili MH. Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med. 2013 Jun 12;11(1):145. [Epub ahead of print]. PMCID: PMC3694475

Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, Taghian A, Wickerham DL, Wolmark N. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012 Nov 10;30(32):3960-6. PMCID: PMC3488269

Stevenson CE, Nagahashi M, Ramachandran S, Yamada A, Bear HD, Takabe K. Bevacizumab and breast cancer: what does the future hold? Future Oncol. 2012 Apr;8(4):403-14. PMCID: PMC3464486

Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, Dumur C, Wang E, Ramakrishnan V, Wang XY, Bear HD, Marincola FM, Manjili MH. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat. 2012 Feb;131(3):871-80. PMCID: PMC3431022

Bear HD, Tang G, Rastogi P, Geyer CE, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012 Jan 26;366(4):310-20. PMCID: PMC3401076

Mian OY, Wang SZ, Zhu SZ, Gnanapragasam MN, Graham L, Bear HD, Ginder GD. Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells. Mol Cancer Res. 2011 Aug;9(8):1152-62. PMCID: PMC3157569

Kurdziel KA, Kalen JD, Hirsch JI, Wilson JD, Bear HD, Logan J, McCumisky  J, Moorman-Sykes K, Adler S, Choyke PL. Human dosimetry and preliminary tumor distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET/CT.J Nucl Med. 2011 Sep;52(9):1339-45. PMCID: PMC3224978

Zhang Q, Sturgill JL, Kmieciak M, Szczepanek K, Derecka M, Koebel C, Graham LJ, Dai Y, Chen S, Grant S, Cichy J, Shimoda K, Gamero A, Manjili M, Bear H, Conrad D, Larner AC. The role of Tyk2 in regulation of breast cancer growth. J Interferon Cytokine Res. 2011 Sep;31(9):671-7. PMCID: PMC3173819

Kmieciak M, Basu D, Payne KK, Toor A, Yacoub A, Wang XY, Smith L, Bear HD, Manjili MH. Activated NK T cells and NK cells render T cells resistant to MDSC and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J Immunol. 2011 Jul 15;187(2):708-17. PMCID: PMC3131490

Kmieciak M, Payne KK, Idowu MO, Grimes MM, Graham L, Ascierto ML, Wang E, Wang XY, Bear HD, Manjili MH. Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure. J Transl Med. 2011 Mar 31;9:35. PMCID: PMC3076247

Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b−Gr1− bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat. 2010 Aug;123(1):39-49. PMCID: PMC3095485

Miller CH, Graham L, Bear HD. Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma. BMC Immunol. 2010; 11: 54. PMCID: PMC2998465